Evaxion Biotech AS (EVAX) — Strategic Asset Allocation Index
Evaxion Biotech AS (EVAX) has a Strategic Asset Allocation Index of 23.4% as of June 2022. Strategic assets (PP&E of $4.72 Million plus long-term investments of $-) total $4.72 Million, measured against net assets of $20.15 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Evaxion Biotech AS balance sheet quality to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Evaxion Biotech AS Strategic Asset Allocation Index (2019–2021)
This chart shows how Evaxion Biotech AS's Strategic Asset Allocation Index has evolved across 3 annual periods from 2019 to 2021. As of June 2022, the index stands at 23.4%, representing strategic assets of $4.72 Million against net assets of $20.15 Million USD. For live market cap and overall valuation, see Evaxion Biotech AS stock valuation.
Annual Strategic Asset Allocation Index for Evaxion Biotech AS (2019–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Evaxion Biotech AS from 2019 to 2021, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See EVAX net asset value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 16.0% | $5.17 Million | $5.17 Million | $- | $32.44 Million | ▲ +12.8 pp |
| 2020 | 3.1% | $221.00K | $221.00K | $- | $7.04 Million | ▲ +2.1 pp |
| 2019 | 1.1% | $101.00K | $101.00K | $- | $9.36 Million | — |